Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


French Actos risk not seen with other diabetes drugs, and only in bladder cancer

This article was originally published in Scrip

Executive Summary

Not long after the furore over its tardy withdrawal of Servier's antidiabetic Mediator, the French medicines regulator Afssaps has now said it will suspend Takeda's diabetes drugs Actos and Competact, both formulated with pioglitazone. The move follows results of a French study indicating an increased risk of bladder cancer but comes before the European Medicines Agency has concluded its own benefit:risk review of the drugs. The Japanese drug regulator had not taken any action over Actos by close of business on 10 June, but Germany's Federal Institute for Drugs and Medical Devices has announced that it has suspended the use of the drug.

You may also be interested in...

WHO Launches Action Plan For Cross-Country Market Access Collaborations

While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.

EU Orphan Law Under Attack Over ‘Flawed Incentives’

The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.

UK Pulls Out Of Unified Patent Court Agreement

The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts